01 — At a Glance
The Pain Business: Where Profits Hurt Less Than Stock Returns
- 52-Week High / Low₹127 / ₹57.5
- Q3 FY26 Revenue₹580 Cr
- Q3 FY26 PAT₹29 Cr
- TTM EPS₹3.96
- Annualised EPS (Q3 Avg × 4)₹2.80
- Book Value / Share₹59.7
- Price to Book1.24x
- ROCE8.86%
- Debt / Equity0.09x
- Return (3 Months)-13.7%
Flash Summary: IOL just delivered Q3 FY26 PAT of ₹29 crore — up 40.9% YoY. Revenue is up 10.9% at ₹580 crore. The company has near-zero debt (0.09x), generates ₹600+ crore in annual profits, and controls 35% of the global Ibuprofen market. Yet the stock trades at 18.2x P/E and has crashed 13.7% in three months. This is either a screaming bargain or investors are smarter than we think. Spoiler: probably both.
02 — Introduction
The Accidental Global Champion Nobody Talks About
There’s a small town called Barnala in Punjab. Population: around 100,000 humans. Chemical capacity: nearly 2 lakh metric tonnes per year. Since 1986, IOL Chemicals has been quietly building medicine in this town while the rest of India dreams about IPO riches and stock splits.
IOL is the largest manufacturer of Ibuprofen on Earth. Not India. Earth. 35% global market share. Every time your grandmother had a headache in Switzerland, or your cousin’s joint pain flared in Brazil, there’s a decent chance it was IOL’s Ibuprofen that saved the day. The company has zero debt (well, 0.09x), strong cash generation, and a business model that’s literally immune to economic slowdowns — people get sick and need medicine regardless of GDP growth.
The Q3 story is three-act play. Act 1: Revenue up 10.9%, PAT up 40.9%. Act 2: EBITDA margins expanded 100 basis points to 10.7%. Act 3: Share price down 13.7% in three months anyway. It’s like paying ₹1,000 for a perfectly cooked biryani and then complaining the restaurant didn’t give you a free dessert. Let’s break the paradox.
Concall Highlight (Feb 2026): Management said the primary margin driver was capacity utilization hitting 90-95% on Ibuprofen and nearly 100% on Ethyl Acetate. Translation: they’re running flat out and still making more profit. There’s no free lunch in manufacturing, but if you can run your factory at full capacity while competitors struggle, that’s as close as you get.
03 — Business Model: How a Town in Punjab Sells Pills to the World
Backward Integration Is Code for “We Control Our Own Destiny”
Members get full access to every article.
